Press Releases

Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test

Genomic Health, Inc. and Epic Sciences, Inc. announced an exclusive agreement to commercialize Epic Sciences’ novel AR-V7 liquid biopsy test in the United States through Genomic Health’s world-class commercial channel.

Epic Sciences Introduces Sensitive HRD Liquid Biopsy Test for PARP Inhibitor Clinical Trials

Epic Sciences unveiled a liquid biopsy test that more sensitively detects cancers susceptible to PARP inhibitors by targeting homologous recombination deficiency (HRD) in individual circulating tumor cells (CTCs).

Presence of AR-V7 in Circulating Tumor Cells Validated as Predictive Biomarker for Advanced Prostate Cancer Treatment by Memorial Sloan Kettering and Epic Sciences

New Publication: JAMA Oncology 2016. Presence of AR-V7 in Circulating Tumor Cells Validated as Predictive Biomarker for Advanced Prostate Cancer Treatment by Memorial Sloan Kettering and Epic Sciences

Epic Sciences to Present at Molecular Medicine Tri-Con 2016

Epic Sciences, Inc. , announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the Molecular Medicine Tri-Con 2016, taking place at the Moscone Convention Center, San Francisco.

Avera Medical Group And Epic Sciences Collaborate on Cancer Precision Medicine Clinical Trials

SAN DIEGO, January 28, 2016 /PRNewswire/ -- Epic Sciences, Inc. and Avera Medical Group announced today a collaboration on feasibility studies to better understand the effectiveness of personalized cancer treatments as part of novel ovarian and breast…

Epic Sciences Receives CAP Accreditation

SAN DIEGO, Jan 11, 2016 /PRNewswire/ -- Epic Sciences announced today that they have received notice of their accreditation from the College of American Pathologists (CAP) for its San Diego laboratory. The CAP Laboratory Accreditation Program is…

Circulating Tumor Cells Linked with Treatment Resistance and Response in Prostate Cancer Patients

SAN DIEGO, Jan. 4, 2016 /PRNewswire/ — Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only…

Epic Sciences Enters into 35th Pharma Collaboration to Advance Companion Diagnostics for New Targeted Therapeutics

SAN DIEGO, Dec. 11, 2015 /PRNewswire/ — Epic Sciences, a private biotech company that develops novel diagnostics to personalize and advance the treatment and management of cancer, announced today that it has signed its 35th collaboration agreement with…

Epic Sciences' Chief Scientific Officer Named Leading Global Thinker by Foreign Policy Magazine

SAN DIEGO, Dec. 1, 2015 /PRNewswire/ — Epic Sciences' Chief Scientific Officer Dena Marrinucci, Ph.D., was named today by Foreign Policy magazine as one of this year’s 100 Leading Global Thinkers. Marrinucci will be honored at a gala in Washington, D.C.…

Epic Sciences Partners with University of Pennsylvania's Abramson Cancer Center on Cancer Therapy Discoveries through Liquid Biopsy

SAN DIEGO, November 13, 2015 /PRNewswire/ -- Epic Sciences, Inc. announced today a collaboration with the Abramson Cancer Center of the University of Pennsylvania (Penn) on multiple studies to explore biomarkers, identified by analysis of circulating…